Objective-To investigate the incidence of fatal myocardial infarction in women in the two randomised arms of the Scottish adjuvant tamoxifen trial.
Introduction
Tamoxifen is a non-steroidal antioestrogen and is considered to be the front line endocrine treatment for breast cancer. It is widely used in postmenopausal women both as treatment for advanced disease' 2 and as adjuvant treatment in early disease, when it has been shown to delay recurrence and increase survival.3
Increasing numbers of premenopausal women are also now receiving tamoxifen as adjuvant treatment. 4 Although tamoxifen was given for up to two years in most early clinical trials, evidence is growing that better results may be obtained with Table I shows the cause of death in the 451 women who died (200 from the adjuvant arm and 251 from the observation arm). Evidence from postmortem examination was available for 38 women. We restricted the analysis to those who had a fatal myocardial infarction in the absence of known or suspected systemic cancer.
Ten women in the adjuvant tamoxifen arm of the trial were recorded as having died of acute myocardial infarction. The median age of these women was 71 (range 65-77) years and the median duration of exposure to tamoxifen was 29 (9-93) months. Nine of the women were still receiving tamoxifen at the time of death and one had stopped treatment two months before her death. In the observation arm 25 women died of acute myocardial infarction at a median age of 73 (59-80) years. Twenty one of these women had had no known exposure to tamoxifen. The four other women were all receiving tamoxifen when they died: one had received adjuvant tamoxifen for four months in error, two women had been successfully treated for local or regional recurrence with local therapy and tamoxifen for 12 and 13 months, and one woman had received tamoxifen for 14 months after excision of a contralateral primary breast tumour. Table II Women in the adjuvant arm were significantly less likely to die of myocardial infarction than were women in the observation arm (X2=6-88) p=00087). Women receiving adjuvant tamoxifen have a significantly increased survival'3 and hence a longer time at risk of dying from a cause other than breast cancer. Thus, the beneficial effect of tamoxifen on myocardial infarction could be greater than is apparent from these data. Survival analysis using death from myocardial infarction as the end point confirms the significance of this result (p=0O0054, Mantel-Cox); the hazard ratio was 0-37 (95% confidence interval 0 18 to 0-77).
Twenty seven women died of vascular diseases, which included cerebrovascular accident, congestive cardiac failure, chronic ischaemic heart disease, and mitral valve disease. We found no difference in the distribution of these various causes within the adjuvant and observation arms of the trials.
Discussion
Tamoxifen exhibits a range of complex pharmacological properties, and may behave as an oestrogen or an antioestrogen depending on the target site. ' whether adjuvant tamoxifen has a similar effect on the incidence of non-fatal myocardial infarction. 
